04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
23:27 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

Sound reports Phase Ib data for SPI-1005 in Meniere's disease

In October, Sound Pharmaceuticals Inc. (Seattle, Wash.) reported top-line data from a Phase Ib trial in 40 patients with Meniere’s disease showing that oral ebselen (SPI-1005) for 21 days improved low frequency hearing in 55%...
20:32 , Nov 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; solid tumors Cell culture and mouse studies suggest inhibiting GPX4 could help treat relapsing, drug-resistant cancers. In human breast, lung, melanoma and ovarian cancer cell lines, a GPX4 inhibitor tool compound induced higher...
23:32 , Nov 2, 2017 |  BC Extra  |  Preclinical News

Researchers suggest GPX4 inhibition to treat drug-resistant cancer

In a paper published in Nature , researchers at the University of California San Francisco and colleagues showed that persister cells from a range of cancers depend on glutathione peroxidase 4 (GPX4) for survival, suggesting...
20:50 , Oct 10, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs A SNP on the GPX3 - Tnip1 locus could help predict the risk of ALS. Genome-wide association studies in 13,811 ALS patients and 26,325 healthy volunteers identified an association between the disease and...
16:54 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

Sound begins Phase IIb of SPI-1005 for Meniere's disease

Sound Pharmaceuticals Inc. (Seattle, Wash.) began the double-blind, placebo-controlled Phase IIb SPI-1005-251 trial of ebselen (SPI-1005) for 28 days in 120 patients with Meniere's disease. The trial will evaluate safety and include assessments of hearing...
19:41 , Jun 2, 2017 |  BioCentury  |  Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
01:21 , Jan 27, 2017 |  BC Innovations  |  Targets & Mechanisms

Death metal

The findings in two high profile papers on ferroptosis could be the nudge the fledgling field needs to gain the attention of drug developers. The process is the latest cell death pathway to offer up...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

Ebselen: Phase Ib started

Sound began a double-blind, placebo-controlled, U.S. Phase Ib trial to evaluate 200, 400 and 600 mg oral SPI-1005 twice daily for 21 days in about 40 patients. Sound Pharmaceuticals Inc. , Seattle, Wash.   Product:...
07:00 , Oct 15, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Clostridium difficile toxin B (TcdB)

Infectious disease INDICATION: Clostridium In vitro and mouse studies suggest ebselen could be repurposed to treat Clostridium difficile infection (CDI). Screening of a small molecule library in an assay for binding to the cysteine protease...